| Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases. It also provides Yescarta, a chimeric antigen receptor T cell therapy for adult patients with relapsed or refractory large B-cell lymphoma; Zydelig, a PI3K delta inhibitor for certain blood cancers; Letairis, an oral formulation of an endothelin receptor antagonist for pulmonary arterial hypertension; Ranexa, a tablet to treat chronic angina; and Lexiscan, an injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging. In addition, the company offers Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; Tamiflu, an oral antiviral capsule for the treatment and prevention of influenza A and B; AmBisome, an antifungal agent to treat serious invasive fungal infections; and Macugen, an anti-angiogenic oligonucleotide to treat neovascular age-related macular degeneration. Further, it has product candidates in various stages of development for the treatment of HIV/AIDS and liver diseases, hematology/oncology, inflammation/respiratory diseases, and others. The company markets its products through its commercial teams; and in conjunction with third-party distributors and corporate partners. Gilead Sciences, Inc. has collaboration agreements with Bristol-Myers Squibb Company, Janssen Sciences Ireland UC, Japan Tobacco Inc., and Galapagos NV. The company was founded in 1987 and is headquartered in Foster City, California. |
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| MARTIN JOHN C | Director | Sep 04 | Option Exercise | 23.60 | 50,000 | 1,180,000 | 3,067,762 | Sep 06 05:24 PM | | MARTIN JOHN C | Director | Sep 04 | Sale | 74.16 | 50,000 | 3,708,034 | 3,017,762 | Sep 06 05:24 PM | | MARTIN JOHN C | Director | Aug 01 | Option Exercise | 23.60 | 50,000 | 1,180,000 | 3,067,762 | Aug 03 04:41 PM | | MARTIN JOHN C | Director | Aug 01 | Sale | 77.85 | 50,000 | 3,892,650 | 3,017,762 | Aug 03 04:41 PM | | MARTIN JOHN C | Director | Jul 02 | Option Exercise | 23.60 | 50,000 | 1,180,000 | 3,067,762 | Jul 05 08:00 PM | | MARTIN JOHN C | Director | Jul 02 | Sale | 70.81 | 50,000 | 3,540,282 | 3,017,762 | Jul 05 08:00 PM | | MARTIN JOHN C | Director | Jun 01 | Option Exercise | 23.60 | 50,000 | 1,180,000 | 3,067,762 | Jun 05 07:34 PM | | MARTIN JOHN C | Director | Jun 01 | Sale | 68.13 | 50,000 | 3,406,495 | 3,017,762 | Jun 05 07:34 PM | | Cogan John Francis | Director | May 04 | Option Exercise | 26.62 | 5,836 | 155,325 | 58,455 | May 08 01:59 PM | | MILLIGAN JOHN F | President and CEO | May 04 | Option Exercise | 27.07 | 80,000 | 2,165,600 | 1,294,306 | May 08 06:29 PM | | Cogan John Francis | Director | May 04 | Sale | 65.09 | 5,836 | 379,885 | 52,619 | May 08 01:59 PM | | MARTIN JOHN C | Director | May 01 | Option Exercise | 23.60 | 50,000 | 1,180,000 | 3,067,762 | May 03 01:07 PM | | MARTIN JOHN C | Director | May 01 | Sale | 72.19 | 50,000 | 3,609,660 | 3,017,762 | May 03 01:07 PM | | Cogan John Francis | Director | Apr 27 | Option Exercise | 26.62 | 5,833 | 155,245 | 58,452 | Apr 30 05:39 PM | | Cogan John Francis | Director | Apr 27 | Sale | 73.91 | 5,833 | 431,117 | 52,619 | Apr 30 05:39 PM | | Cogan John Francis | Director | Apr 20 | Option Exercise | 26.62 | 5,833 | 155,245 | 58,452 | Apr 23 07:16 PM | | Cogan John Francis | Director | Apr 20 | Sale | 73.74 | 5,833 | 430,130 | 52,619 | Apr 23 07:16 PM | | Cogan John Francis | Director | Apr 13 | Option Exercise | 26.62 | 5,833 | 155,245 | 58,452 | Apr 16 06:45 PM | | Cogan John Francis | Director | Apr 13 | Sale | 75.56 | 5,833 | 440,741 | 52,619 | Apr 16 06:45 PM | | Cogan John Francis | Director | Apr 06 | Option Exercise | 26.62 | 5,833 | 155,245 | 58,452 | Apr 09 06:41 PM | | Cogan John Francis | Director | Apr 06 | Sale | 74.47 | 5,833 | 434,384 | 52,619 | Apr 09 06:41 PM | | Cogan John Francis | Director | Apr 02 | Option Exercise | 26.62 | 5,833 | 155,245 | 58,452 | Apr 04 04:23 PM | | MARTIN JOHN C | Director | Apr 02 | Option Exercise | 23.60 | 50,000 | 1,180,000 | 3,067,762 | Apr 04 07:34 PM | | MARTIN JOHN C | Director | Apr 02 | Sale | 73.14 | 50,000 | 3,656,806 | 3,017,762 | Apr 04 07:34 PM | | Cogan John Francis | Director | Apr 02 | Sale | 74.93 | 5,833 | 437,067 | 52,619 | Apr 04 04:23 PM | | Cogan John Francis | Director | Mar 23 | Option Exercise | 26.62 | 5,833 | 155,245 | 58,452 | Mar 26 06:48 PM | | Cogan John Francis | Director | Mar 23 | Sale | 75.02 | 5,833 | 437,588 | 52,619 | Mar 26 06:48 PM | | Cogan John Francis | Director | Mar 16 | Option Exercise | 26.62 | 5,833 | 155,245 | 58,452 | Mar 20 01:28 PM | | Cogan John Francis | Director | Mar 16 | Sale | 80.09 | 5,833 | 467,138 | 52,619 | Mar 20 01:28 PM | | Cogan John Francis | Director | Mar 12 | Option Exercise | 26.62 | 5,833 | 155,245 | 58,452 | Mar 13 04:29 PM | | Cogan John Francis | Director | Mar 12 | Sale | 80.93 | 5,833 | 472,065 | 52,619 | Mar 13 04:29 PM | | MARTIN JOHN C | Executive Chairman | Mar 01 | Option Exercise | 23.60 | 50,000 | 1,180,000 | 3,067,762 | Mar 05 06:54 PM | | Alton Gregg H | EVP,Corporate &Medical Affairs | Mar 01 | Option Exercise | 40.56 | 17,250 | 699,660 | 69,426 | Mar 05 07:04 PM | | MOORE NICHOLAS G | Director | Mar 01 | Option Exercise | 0.00 | 178 | 0 | 12,233 | Mar 05 08:42 PM | | Alton Gregg H | EVP,Corporate &Medical Affairs | Mar 01 | Sale | 78.69 | 25,000 | 1,967,315 | 44,426 | Mar 05 07:04 PM | | MARTIN JOHN C | Executive Chairman | Mar 01 | Sale | 78.65 | 50,000 | 3,932,375 | 3,017,762 | Mar 05 06:54 PM | | Washington Robin L | EVP, CFO | Feb 28 | Sale | 80.31 | 5,000 | 401,566 | 105,405 | Mar 02 06:47 PM | | Alton Gregg H | EVP,Corporate &Medical Affairs | Feb 20 | Sale | 81.54 | 14,435 | 1,176,992 | 0 | Feb 21 06:51 PM | | YOUNG KEVIN | Chief Operating Officer | Feb 10 | Option Exercise | 0.00 | 908 | 0 | 16,237 | Feb 13 04:58 PM | | WILSON GAYLE E | Director | Feb 09 | Option Exercise | 26.62 | 60,000 | 1,596,900 | 182,258 | Feb 13 05:24 PM | | WILSON GAYLE E | Director | Feb 09 | Sale | 77.92 | 60,000 | 4,675,080 | 122,258 | Feb 13 05:24 PM | | MARTIN JOHN C | Executive Chairman | Feb 01 | Option Exercise | 23.60 | 50,000 | 1,180,000 | 3,046,766 | Feb 05 08:38 PM | | Alton Gregg H | EVP,Corporate &Medical Affairs | Feb 01 | Option Exercise | 40.56 | 17,250 | 699,660 | 62,738 | Feb 05 09:20 PM | | YOUNG KEVIN | Chief Operating Officer | Feb 01 | Option Exercise | 0.00 | 620 | 0 | 15,547 | Feb 02 09:14 PM | | Alton Gregg H | EVP,Corporate &Medical Affairs | Feb 01 | Sale | 83.51 | 25,000 | 2,087,860 | 37,738 | Feb 05 09:20 PM | | MARTIN JOHN C | Executive Chairman | Feb 01 | Sale | 83.56 | 50,000 | 4,177,824 | 2,996,766 | Feb 05 08:38 PM | | Meyers James R | EVP Worldwide Commercial Ops | Jan 16 | Option Exercise | 21.58 | 100,000 | 2,157,500 | 102,715 | Jan 18 06:31 PM | | Meyers James R | EVP Worldwide Commercial Ops | Jan 16 | Sale | 80.24 | 100,000 | 8,024,364 | 2,715 | Jan 18 06:31 PM | | Alton Gregg H | EVP Comm&Acs ALA, Corp&Med Aff | Jan 11 | Option Exercise | 36.02 | 25,875 | 932,062 | 75,488 | Jan 16 05:42 PM | | Alton Gregg H | EVP Comm&Acs ALA, Corp&Med Aff | Jan 11 | Sale | 79.00 | 30,000 | 2,370,000 | 45,488 | Jan 16 05:42 PM | | MARTIN JOHN C | Executive Chairman | Jan 02 | Option Exercise | 23.60 | 50,000 | 1,180,000 | 3,046,766 | Jan 04 07:54 PM | | Alton Gregg H | EVP Comm&Acs ALA, Corp&Med Aff | Jan 02 | Option Exercise | 24.91 | 8,625 | 214,806 | 64,613 | Jan 04 08:05 PM | | Alton Gregg H | EVP Comm&Acs ALA, Corp&Med Aff | Jan 02 | Sale | 73.87 | 15,000 | 1,108,019 | 49,613 | Jan 04 08:05 PM | | MARTIN JOHN C | Executive Chairman | Jan 02 | Sale | 73.62 | 50,000 | 3,681,235 | 2,996,766 | Jan 04 07:54 PM | | Alton Gregg H | EVP Comm&Acs ALA, Corp&Med Aff | Dec 01 | Option Exercise | 24.91 | 8,625 | 214,806 | 70,988 | Dec 05 06:17 PM | | MARTIN JOHN C | Executive Chairman | Dec 01 | Option Exercise | 21.58 | 73,333 | 1,582,159 | 3,070,099 | Dec 05 07:49 PM | | MARTIN JOHN C | Executive Chairman | Dec 01 | Sale | 74.98 | 73,333 | 5,498,385 | 2,996,766 | Dec 05 07:49 PM | | Alton Gregg H | EVP Comm&Acs ALA, Corp&Med Aff | Dec 01 | Sale | 74.64 | 15,000 | 1,119,552 | 55,988 | Dec 05 06:17 PM | | MILLIGAN JOHN F | President and CEO | Nov 13 | Option Exercise | 21.58 | 220,000 | 4,746,500 | 1,385,924 | Nov 15 03:19 PM | | MILLIGAN JOHN F | President and CEO | Nov 13 | Sale | 72.88 | 220,000 | 16,034,678 | 1,165,924 | Nov 15 03:19 PM | | Meyers James R | EVP Worldwide Commercial Ops | Nov 05 | Option Exercise | 0.00 | 4,500 | 0 | 7,215 | Nov 07 05:47 PM | | Alton Gregg H | EVP Comm&Acs ALA, Corp&Med Aff | Nov 01 | Option Exercise | 24.91 | 8,625 | 214,806 | 77,363 | Nov 03 06:59 PM | | MARTIN JOHN C | Executive Chairman | Nov 01 | Option Exercise | 21.58 | 73,333 | 1,582,159 | 3,070,099 | Nov 03 07:04 PM | | MARTIN JOHN C | Executive Chairman | Nov 01 | Sale | 75.13 | 73,333 | 5,509,697 | 2,996,766 | Nov 03 07:04 PM | | Alton Gregg H | EVP Comm&Acs ALA, Corp&Med Aff | Nov 01 | Sale | 74.82 | 15,000 | 1,122,285 | 62,363 | Nov 03 06:59 PM | | MARTIN JOHN C | Executive Chairman | Oct 02 | Option Exercise | 21.58 | 73,333 | 1,582,159 | 3,070,099 | Oct 04 07:19 PM | | Alton Gregg H | EVP Comm&Acs ALA, Corp&Med Aff | Oct 02 | Option Exercise | 24.91 | 17,250 | 429,611 | 93,738 | Oct 04 07:26 PM | | Alton Gregg H | EVP Comm&Acs ALA, Corp&Med Aff | Oct 02 | Sale | 82.65 | 25,000 | 2,066,307 | 68,738 | Oct 04 07:26 PM | | MARTIN JOHN C | Executive Chairman | Oct 02 | Sale | 82.56 | 73,333 | 6,054,319 | 2,996,766 | Oct 04 07:19 PM |
|
